At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
Cabozantinib S-malate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
In Brief
A Phase 1 clinical trial evaluating Cabozantinib S-malate, Laboratory Biomarker Analysis, and 1 other intervention for Advanced Malignant Solid Neoplasm and 4 related conditions. Completed, enrolled 36 participants across 20 sites.
Detailed Summary
This phase I trial studies the side effects and best dose of cabozantinib s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and human immunodeficiency virus. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Solid Neoplasm, HIV Infection, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Solid Neoplasm
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartJun 2013
Primary CompletionMay 2019
Study CompletionMay 2021
TodayJul 2026
First PostedApr 2, 2013
Enrollment StartJun 21, 2013
Primary CompletionMay 22, 2019
Study CompletionMay 12, 2021
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 13.3 years ago
Interventions
Cabozantinib S-malatedrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies